Article Text

Download PDFPDF
Ondansetron and irritable bowel syndrome
  1. Pavit Luthra1,
  2. Alexander C Ford1,2
  1. 1Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK
  2. 2Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
  1. Correspondence to Alexander C Ford, Leeds Gastroenterology Institute, Room 125, 4th Floor, Bexley Wing, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK; alexf12399{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read the paper by Garsed et al,1 which revives interest in 5-hydroxytryptamine (5-HT) receptor antagonists as treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). As a highly prevalent functional gastrointestinal (GI) disorder,2 without a known organic pathology to target, IBS continues to be challenging to treat. Interest in agents acting on 5-HT receptors selectively is not novel, with alosetron, the most well-studied 5-HT3 antagonist, demonstrating efficacy in treating IBS-D.3 However, cases of severe constipation and ischaemic colitis led to the withdrawal of the drug. Ondansetron first demonstrated effects on GI transit over …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles